FDA Panel Rejects AstraZeneca Drug  BETHESDA, Md. (Reuters) - A U.S. panel of medical experts  recommended on Friday that U.S. regulators reject AstraZeneca's  &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=AZN.L target=/stocks/quickinfo/fullquote"&gt;AZN.L&lt;/A&gt; &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=AZN.N target=/stocks/quickinfo/fullquote"&gt;AZN.N&lt;/A&gt; application to sell its anti-clotting drug  Exanta.